Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 10;14(11):101197. doi: 10.1016/j.tranon.2021.101197

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Published by Elsevier Inc.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 1 — Interferon-related genes and global RNA editing are unable to segregate patients by response. (A) Heat map of interferon and interferon-related gene expression changes in nonresponder (NR) and responder (R) patients treated with Pembrolizumab. (B) ADAR1, ADAR2, and ADAR3 gene expression levels in nonresponder and responder patients from patients treated with Pembrolizumab. (C) Total AG/TC RNA editing sites vs. total spots in nonresponder (red) and responder (blue) patients. (D) Heat map of interferon and interferon-related gene expression changes in nonresponder (NR), responder (R), stable disease (SB), and unknown (UNK) patients treated with Nivolumab. (E) ADAR1, ADAR2 and ADAR3 gene expression levels in nonresponder and responder patients treated with Nivolumab. (F) Total AG/TC RNA editing sites vs. total spots in nonresponder (red), responder (blue), and stable disease (orange) patients (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).